Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 9, 2025

ADAR1 (15.8.6)

RRID:AB_2222767
Type: Antibody

Proper Citation

(Santa Cruz Biotechnology Cat# sc-73408, RRID:AB_2222767)

Antibody Information

URL: http://antibodyregistry.org/AB_2222767

Proper Citation: (Santa Cruz Biotechnology Cat# sc-73408, RRID:AB_2222767)

Target Antigen: ADAR1 (15.8.6)

Host Organism: human

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: ELISA; Western Blot; Immunofluorescence; Immunohistochemistry; WB, IP, IF, IHC(P)

Antibody Name: ADAR1 (15.8.6)

Description: This monoclonal targets ADAR1 (15.8.6)

Target Organism: rat, mouse, human

Antibody ID: AB_2222767

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-73408

Record Creation Time: 20231110T072220+0000

Record Last Update: 20241115T013122+0000

Ratings and Alerts

No rating or validation information has been found for ADAR1 (15.8.6).

No alerts have been found for ADAR1 (15.8.6).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Dai Y, et al. (2024) Increased viral tolerance mediates by antiviral RNA interference in bat cells. Cell reports, 43(8), 114581.

Hosseini A, et al. (2024) Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. Cell reports, 43(2), 113684.

Gan WL, et al. (2024) Hepatocyte-macrophage crosstalk via the PGRN-EGFR axis modulates ADAR1-mediated immunity in the liver. Cell reports, 43(7), 114400.

Belur NR, et al. (2024) Nuclear aggregates of NONO/SFPQ and A-to-I-edited RNA in Parkinson's disease and dementia with Lewy bodies. Neuron, 112(15), 2558.

Cottrell KA, et al. (2024) Induction of Viral Mimicry Upon Loss of DHX9 and ADAR1 in Breast Cancer Cells. Cancer research communications, 4(4), 986.

van Gemert F, et al. (2024) ADARp150 counteracts whole genome duplication. Nucleic acids research, 52(17), 10370.

Sinigaglia K, et al. (2024) An ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA inhibits PKR activation. Cell reports, 43(8), 114618.

Hu SB, et al. (2023) ADAR1p150 prevents MDA5 and PKR activation via distinct mechanisms to avert fatal autoinflammation. Molecular cell, 83(21), 3869.

Oka M, et al. (2023) Phase-separated nuclear bodies of nucleoporin fusions promote condensation of MLL1/CRM1 and rearrangement of 3D genome structure. Cell reports, 42(8), 112884.

Fu T, et al. (2022) Multifaceted role of RNA editing in promoting loss-of-function of PODXL in cancer. iScience, 25(8), 104836.

de Reuver R, et al. (2021) ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation. Cell reports, 36(6),

109500.

Suzuki H, et al. (2021) Proline-arginine poly-dipeptide encoded by the C9orf72 repeat expansion inhibits adenosine deaminase acting on RNA. Journal of neurochemistry, 158(3), 753.

Tang Q, et al. (2021) Adenosine-to-inosine editing of endogenous Z-form RNA by the deaminase ADAR1 prevents spontaneous MAVS-dependent type I interferon responses. Immunity, 54(9), 1961.

Nakahama T, et al. (2021) Mutations in the adenosine deaminase ADAR1 that prevent endogenous Z-RNA binding induce Aicardi-Goutières-syndrome-like encephalopathy. Immunity, 54(9), 1976.

Karki R, et al. (2021) ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis. Cell reports, 37(3), 109858.

Ilik ?A, et al. (2020) SON and SRRM2 are essential for nuclear speckle formation. eLife, 9.

Freund EC, et al. (2020) Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing. Cell reports, 31(7), 107656.